Non ischemic Cardiomyopathies and Cardiac MRI
Transcript of Non ischemic Cardiomyopathies and Cardiac MRI
Non ischemic Cardiomyopathies
and Cardiac MRI
Mahi L. Ashwath MD, MBA, FACC,
FASE, FSCMR
President, Iowa ACC
Associate Professor of Medicine and Radiology
Division of Cardiology
University of Iowa Hospitals and Clinics1
Normal Cardiac MRI
Normal Cardiac MRI
LAD infarct – ischemic cardiomyopathy
5
Cardiomyopathies
Genetic Mixed Acquired
Hypertrophic
Cardiomyopathy
Dilated Cardiomyopathy Myocarditis
Arrhythmogenic right
ventricular
cardiomyopathy
Restrictive
Cardiomyopathy
Stress / Takotsubo
Cardiomyopathy
Non compaction
cardiomyopathy
Peripartum
Cardiomyopathy
Storage
Cardiomyopathy
Tachycardia Mediated
Cardiomyopathy
Dilated Cardiomyopathy
Dilated Cardiomyopathy
• Dilation and impaired contraction of one or both ventricles
• Usually associated with increase in total cardiac mass
• Incidence 5-8 cases per 100,000 population
• Upto 14% of middle aged and elderly population have asymptomatic
LV systolic dysfunction
• Causes:
▪ Viruses
▪ Gene mutations
• Distinguish from
▪ Ischemic Cardiomyopathy
▪ Valvular Cardiomyopathy
Hypertrophic Cardiomyopathy
9
• Variety of mutations associated with hypertrophy of the LV and occasionally the RV
• Prevalence 0.2 – 0.5%
• Histology
• Hypertrophied myocytes with
• Myocardial disarray
• Microvasculature with decreased luminal cross sectional area
• Impaired vasodilatory capacity
• Abnormalities
• LV outflow obstruction
• Diastolic dysfunction
• Myocardial ischemia
• Mitral regurgitation
Hypertrophic Cardiomyopathy
10
Hypertrophic Cardiomyopathy – Presentation -
Symptoms
• Heart failure
• Fatigue
• Dyspnea
• Myocardial ischemia
• Chest pain
• Arrhythmia
• Palpitations
• Pre-syncope or syncope
• Systolic murmurs:
• Obstruction murmur –
▪ Harsh crescendo – decrescendo murmur
▪ apex and LLSB –
▪ increases with increase in obstruction – upright
posture, Valsalva, post PVC or with nitroglycerin
▪ Decrease with sitting, handgrip and following passive
elevation of the legs
• Mitral regurgitation with a posterior jet
▪ mid – late systolic murmur at apex
Hypertrophic Cardiomyopathy – Presentation -
Signs
Diagnostic testing
• Goals:
• To establish the diagnosis of HCM
• To identify the presence or severity of obstruction
• Assess mitral regurgitation
• Risk of arrhythmia
• Overall LV function
Tests performed:
• EKG
• Prominent abnormal Q waves in the inferior and lateral leads – due to
septal depolarization of the hypertrophied myopathic tissue
• Deeply inverted and prominent T waves with apical variant of HCM
• Echo
• Left ventricular hypertrophy
• unexplained increased LV wall thickness ≥15 mm systolic anterior motion
(SAM) of the mitral valve
• LVOT obstruction
• Ambulatory EKG monitoring
• assessment for ventricular arrhythmias and risk for sudden cardiac death
• Exercise testing
• abnormal blood pressure [BP] response to exercise) and for the assessment
of LVOT gradient
• Cardiovascular magnetic resonance
• Genetic Testing
14
Management - To Decrease Obstruction
• Decrease contraction
• Beta-blockers
• Verapamil
• Diltiazem
• Disopyramide
• Maintain afterload
• Avoid vasodilators
• Avoid diuretics
• Increase volume
• Hydration
• Ongoing angina
• Ranolazine
• Persistent Obstruction
• Myectomy
• Alcohol Septal Ablation
• Indication for Myectomy
• LVOT obstruction
• Angina, dyspnea, and/ or syncope resulting in significant impairment in quality
of life
• Symptoms persist despite appropriate medical therapy
• Procedure involves
• Direct removal of septal muscle
• Mitral valve repair
• Apical approach if significant hypertrophy of distal portion of LV
• Complications:
• Excessive removal of tissue – VSD
• LBBB or CHB
• Aortic regurgitation rarely
• Long term outcomes
• Improvement of symptoms
• Lower rate of appropriate ICD discharges
• Improvement of Pulm HTN
• Improved survival compared to obstructed patients
Surgical Myectomy
16
Ablation
• Creates a localized myocardial infarction
• Abnormalities of MV and pap muscle cannot be addressed
• Significant reduction in LVOT gradient, minimal requirement for repeat procedures
• Complications
• Coronary artery dissection
• Pericardial effusion
• Larger MI
• Complete heart block
• Ventricular tachycardia
• ? Arrhythmic death
2011 ACCF/ AHA guidelines for diagnosis and treatment of Hypertrophic Cardiomyopathy
2011 ACCF/ AHA guidelines for diagnosis and treatment of Hypertrophic Cardiomyopathy
19
Risk factors for SCD
2011 ACCF/ AHA guidelines for diagnosis and treatment of Hypertrophic Cardiomyopathy
22
23
Screening
• Genetics:
• Autosomal Dominant
• Genetic Testing:
• Screen first degree relatives
• H&P, ECG, Echo, genetic screening of first degree relatives if a definite HCM
mutation identified
• No screening up to age 12, unless high risk
• Annually ages 12-18 years
• Adults – every 5 years, usually up to age 40-50 years
Apical Hypertrophic Cardiomyopathy
EKG
Strain pattern – Blueberry on top
30
Apical Hypertrophic Cardiomyopathy
• No LVOT obstruction, can have mid cavitary obstruction
• Common in East Asian populations
• No or mild symptoms
• Audible and palpable S4
• Giant negative T waves on EKG
• Spade like configuration of the LV on echo and MRI
• Associated apical wall motion abnormalities, including
hypokinesis and aneurysm
Fabry Cardiomyopathy
Fabry Cardiomyopathy
Fabry Cardiomyopathy
• HCM mimicker
• Glycogen storage disorder
• Abnormal scar pattern with inferolateral patchy
enhancement
36
Other mimickers
• Aortic Stenosis
• Hypertension
• Athlete’s Heart
• Volume Depletion
• Sub aortic membrane
37
HCM Take Home…
• Diagnosis and differential diagnosis
• Treatment of symptoms
• Avoid vasodilation, dehydration
• Risk of SCD
• Family Screening
Restrictive Cardiomyopathies
40
Amyloidosis
• Amylum - starch (Latin)
• Extracellular deposition of amyloid
• Deposits stained with Congo Red dye display an apple green
birefringence
• Types of Amyloid
• Light chains (AL) - “Primary”
• Systemic AL amyloidosis involves the liver, kidneys,
autonomic and peripheral nervous systems, lung and heart
• Cardiac infiltration is present in most patients with AL
amyloidosis
• Transthyretin (ATTR) - “Senile” or “Familial”
41
Cardiac Amyloidosis
• Heart failure
• Diastolic dysfunction > systolic dysfunction
• Lower extremity edema
• Hepatic congestions, ascites, dyspnea
• Low cardiac output
• Electrophysiologic
• Syncope due to bradyarrhythmias or Advanced AV block or ventricular
arrhythmia
• Heart block
• Tachyarrhythmias
• Low voltages on EKG
• Imaging / Laboratory
• Left ventricular “hypertrophy”
• Elevated troponin
42
Amyloidosis - EKG
43
Amyloidosis - Echo
Strain pattern – apical sparing – cherry on top
45
Amyloidosis – Treatment Strategy
• Treatment of Heart failure
• Diuretics
• Treatment for ATTR Cardiomyopathy
• Tafamidis for – ATTR-ACT trial
• Liver transplant
• Need biopsy for exact type of Amyloidosis
• Affects prognosis
• Treatment of clonal plasma cell disorder
• Chemotherapy
• Stem cell transplant
46
Treatment - cardiac specific
• Diuretics/ salt restriction
• Usually have peripheral edema/ ascites
• Avoid
• Digoxin, beta - blockers, vasodilators
• Orthostatic hypotension
• Midodrine
• Treatment of atrial and ventricular arrhythmias
• Pacemakers
• Bradyarrhythmias - esp ATTR
Endomyocardial Fibrosis
Endomyocardial Fibrosis
Takotsubo Cardiomyopathy
51
Takotsubo Cardiomyopathy
• Synonyms:
• Apical ballooning syndrome
• Broken heart syndrome
• Stress induced cardiomyopathy
• Transient regional dysfunction of the left ventricle
• By definition,
• Absence of angiographic evidence of obstructive CAD or acute plaque rupture, pheochromocytoma, myocarditis
• New EKG abnormalities
• Modest troponin elevation
52
Takotsubo Cardiomyopathy
• Mechanisms:
• Catecholamine excess
• Microvascular dysfunction
• Multivessel coronary artery spasm
• Common WMA - apical,
• can be mid-ventricular, basal, focal and global types
• May have myocardial edema on MRI, but no scar
• Can be due to physiological (males) or psychological (females) stressor
• Supportive and standard CHF care
• Recovery of function
Myocarditis
Myocarditis
55
• Increased risk of sudden cardiac death
• No competitive sports for 3-6 months
• Echo, Holter monitor and stress test prior to clearance
Pericarditis with pericardial inflammation
59
Left ventricular non compaction
• Altered myocardial wall
• Continuity between the LV cavity and deep intra trabecular recesses
• Genetics:
• Sporadic or familial
• Autosomal dominant inheritance is more common than X-linked inheritance or
autosomal recessive inheritance
• Yield of genetic testing in patients with LVNC is around 40 to 50 percent
• Overlap in the genetic loci implicated in the major cardiomyopathies
• LVNC and hypertrophic cardiomyopathy
• LVNC and apical hypertrophic cardiomyopathy
• Co-occurs with congenital heart disease or Wolff-Parkinson-White syndrome
60
Left ventricular Non compaction
• Exercise:
• LVEF <50 percent,
• ECG abnormalities,
• arrhythmia,
• symptomatic presentation,
• and/or a positive family history of cardiomyopathy
• counseled to refrain from competitive endurance sports or weight lifting (similar to patients with hypertrophic cardiomyopathy)
• LV non compaction may be associated with
• Heart failure,
• Thromboembolism
• Ventricular arrhythmias in adults
• Family counseling and screening
• All patients with LVNC should receive family and genetic counseling
Sarcoidosis
Circulation. 2009;120:1969-1977
Pathological correlation of sarcoidosis and sudden death
Tavora et al. Am J Cardiol 2009;104:571–577)
Pathological correlation of sarcoidosis and sudden death
Tavora et al. Am J Cardiol 2009;104:571–577)
ARVC
65
Arrhythmogenic Right Ventricular Cardiomyopathy
• Prevalence of ARVC - 1 in 2000 to 1 in 5000
• Inherited
• Autosomal dominant – most common
• Autosomal recessive
• Part of a syndrome – Naxos disease, Carajal syndrome -
have hyperkeratosis of palms and soles and woolly hair
• Significant number of first degree relatives
• Especially siblings
• Localized or generalized dilatation of the RV and myocardial
thinning in the regions of dilatation - typical findings
• Macroscopically - scarred appearance with fibrous or fibro fatty
replacement of the myocardium
66
Clinical Manifestations
• Many clinically silent and asymptomatic for decades
• Can include
• Palpitations
• syncope
• Chest pain
• Dyspnea
• Sudden cardiac death
• Frequent presentations:
• Palpitations
• Ventricular ectopy
• PVCs, NSVT
67
EKG - Epsilon wave
5-30%
68
ARVC - Management
• Arrhythmias:
• Implantable Cardioverter Defibrillator
• Genetic testing - family screening
• Exercise restriction
• Heart transplant
69
ARVC - Management
• High risk features
• Younger age
• Syncope
• Cardiac arrest or VT
• 2 or more mutations
• LV involvement
• Naxos disease
70
Cardiomyopathies
Genetic Mixed Acquired
Hypertrophic
Cardiomyopathy
Dilated
Cardiomyopathy
Myocarditis
Arrhythmogenic right
ventricular
cardiomyopathy
Restrictive
Cardiomyopathy
Stress / Takotsubo
Cardiomyopathy
Non compaction
cardiomyopathy
Peripartum
Cardiomyopathy
Storage
Cardiomyopathy
Tachycardia
Mediated
Cardiomyopathy
71
Thank you!!!